-
Je něco špatně v tomto záznamu ?
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
K. Trpkov, O. Hes, SR. Williamson, AJ. Adeniran, A. Agaimy, R. Alaghehbandan, MB. Amin, P. Argani, YB. Chen, L. Cheng, JI. Epstein, JC. Cheville, E. Comperat, IW. da Cunha, JB. Gordetsky, S. Gupta, H. He, MS. Hirsch, PA. Humphrey, P. Kapur, F....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
NLK
Free Medical Journals
od 2000 do Před 1 rokem
ProQuest Central
od 2000-01-01 do 2022-12-31
Open Access Digital Library
od 2000-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do 2022-12-31
Health & Medicine (ProQuest)
od 2000-01-01 do 2022-12-31
ROAD: Directory of Open Access Scholarly Resources
od 1988
- MeSH
- lidé MeSH
- nádory ledvin * MeSH
- Světová zdravotnická organizace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature. Key prognostic features for clear cell renal cell carcinoma (RCC) remain WHO/ISUP grade, AJCC/pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation. Accrual of subclonal genetic alterations in clear cell RCC including SETD2, PBRM1, BAP1, loss of chromosome 14q and 9p are associated with variable prognosis, patterns of metastasis, and vulnerability to therapies. Recent National Comprehensive Cancer Network (NCCN) guidelines increasingly adopt immunotherapeutic agents in advanced RCC, including RCC with rhabdoid and sarcomatoid changes. Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. For tumors with 'borderline' features between oncocytoma and chromophobe RCC, a term "oncocytic renal neoplasm of low malignant potential, not further classified" is proposed. Clear cell papillary RCC may warrant reclassification as a tumor of low malignant potential. Tubulocystic RCC should only be diagnosed when morphologically pure. MiTF family translocation RCCs exhibit varied morphologic patterns and fusion partners. TFEB-amplified RCC occurs in older patients and is associated with more aggressive behavior. Acquired cystic disease (ACD) RCC-like cysts are likely precursors of ACD-RCC. The diagnosis of renal medullary carcinoma requires a negative SMARCB1 (INI-1) expression and sickle cell trait/disease. Mucinous tubular and spindle cell carcinoma (MTSCC) can be distinguished from papillary RCC with overlapping morphology by losses of chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22. MTSCC with adverse histologic features shows frequent CDKN2A/2B (9p) deletions. BRAF mutations unify the metanephric family of tumors. The term "fumarate hydratase deficient RCC" ("FH-deficient RCC") is preferred over "hereditary leiomyomatosis and RCC syndrome-associated RCC". A low threshold for FH, 2SC, and SDHB immunohistochemistry is recommended in difficult to classify RCCs, particularly those with eosinophilic morphology, occurring in younger patients. Current evidence does not support existence of a unique tumor subtype occurring after chemotherapy/radiation in early childhood.
Anatomical Pathology Douglass Hanly Moir Pathology Sydney NSW Australia
Cancer Diagnosis and Pathology Group Kolling Institute of Medical Research Sydney NSW Australia
Department of Human Pathology Wakayama Medical University Wakayama Japan
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada
Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA
Department of Pathology Cruces University Hospital Biocruces Bizkaia Institute Bizkaia Spain
Department of Pathology Health Science Center Peking University Beijing China
Department of Pathology Hôpital Tenon Sorbonne University Paris France
Department of Pathology Jinling Hospital Nanjing University School of Medicine Nanjing China
Department of Pathology Mayo Clinic Rochester MN USA
Department of Pathology MD Anderson Cancer Center Houston TX USA
Department of Pathology Memorial Sloan Kettering Cancer Center New York NY USA
Department of Pathology The University of Alabama at Birmingham Birmingham AL USA
Department of Pathology The University of Texas Southwestern Medical Center Dallas TX USA
Department of Pathology Tufts Medical Center Boston MA USA
Department of Pathology University of Washington School of Medicine Seattle Washington USA
Department of Pathology Yale School of Medicine New Haven CT USA
Departments of Pathology and Oncology The Johns Hopkins Medical Institutions Baltimore MD USA
Departments of Pathology and Urology VCU School of Medicine Richmond VA USA
Pathology Department Rede D'OR Sao Luiz Sao Paulo SP Brazil
Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA
Sydney Medical School University of Sydney Sydney NSW Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012373
- 003
- CZ-PrNML
- 005
- 20220506130113.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41379-021-00779-w $2 doi
- 035 __
- $a (PubMed)33664427
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Trpkov, Kiril $u Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. kiril.trpkov@albertaprecisionlabs.ca $1 https://orcid.org/0000000331428846
- 245 10
- $a New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia / $c K. Trpkov, O. Hes, SR. Williamson, AJ. Adeniran, A. Agaimy, R. Alaghehbandan, MB. Amin, P. Argani, YB. Chen, L. Cheng, JI. Epstein, JC. Cheville, E. Comperat, IW. da Cunha, JB. Gordetsky, S. Gupta, H. He, MS. Hirsch, PA. Humphrey, P. Kapur, F. Kojima, JI. Lopez, F. Maclean, C. Magi-Galluzzi, JK. McKenney, R. Mehra, S. Menon, GJ. Netto, CG. Przybycin, P. Rao, Q. Rao, VE. Reuter, RM. Saleeb, RB. Shah, SC. Smith, S. Tickoo, MS. Tretiakova, L. True, V. Verkarre, SE. Wobker, M. Zhou, AJ. Gill
- 520 9_
- $a The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature. Key prognostic features for clear cell renal cell carcinoma (RCC) remain WHO/ISUP grade, AJCC/pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation. Accrual of subclonal genetic alterations in clear cell RCC including SETD2, PBRM1, BAP1, loss of chromosome 14q and 9p are associated with variable prognosis, patterns of metastasis, and vulnerability to therapies. Recent National Comprehensive Cancer Network (NCCN) guidelines increasingly adopt immunotherapeutic agents in advanced RCC, including RCC with rhabdoid and sarcomatoid changes. Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. For tumors with 'borderline' features between oncocytoma and chromophobe RCC, a term "oncocytic renal neoplasm of low malignant potential, not further classified" is proposed. Clear cell papillary RCC may warrant reclassification as a tumor of low malignant potential. Tubulocystic RCC should only be diagnosed when morphologically pure. MiTF family translocation RCCs exhibit varied morphologic patterns and fusion partners. TFEB-amplified RCC occurs in older patients and is associated with more aggressive behavior. Acquired cystic disease (ACD) RCC-like cysts are likely precursors of ACD-RCC. The diagnosis of renal medullary carcinoma requires a negative SMARCB1 (INI-1) expression and sickle cell trait/disease. Mucinous tubular and spindle cell carcinoma (MTSCC) can be distinguished from papillary RCC with overlapping morphology by losses of chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22. MTSCC with adverse histologic features shows frequent CDKN2A/2B (9p) deletions. BRAF mutations unify the metanephric family of tumors. The term "fumarate hydratase deficient RCC" ("FH-deficient RCC") is preferred over "hereditary leiomyomatosis and RCC syndrome-associated RCC". A low threshold for FH, 2SC, and SDHB immunohistochemistry is recommended in difficult to classify RCCs, particularly those with eosinophilic morphology, occurring in younger patients. Current evidence does not support existence of a unique tumor subtype occurring after chemotherapy/radiation in early childhood.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory ledvin $7 D007680
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Hes, Ondrej $u Department of Pathology, Charles University in Prague, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
- 700 1_
- $a Williamson, Sean R $u Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000238981460
- 700 1_
- $a Adeniran, Adebowale J $u Department of Pathology, Yale School of Medicine, New Haven, CT, USA
- 700 1_
- $a Agaimy, Abbas $u Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany $1 https://orcid.org/0000000204458161
- 700 1_
- $a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada
- 700 1_
- $a Amin, Mahul B $u Department of Pathology and Laboratory Medicine and Urology, University of Tennessee Health Science, Memphis, TN, USA
- 700 1_
- $a Argani, Pedram $u Departments of Pathology and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
- 700 1_
- $a Chen, Ying-Bei $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA $1 https://orcid.org/0000000152073648
- 700 1_
- $a Cheng, Liang $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA $1 https://orcid.org/0000000160495293
- 700 1_
- $a Epstein, Jonathan I $u Departments of Pathology, Urology and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
- 700 1_
- $a Cheville, John C $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Comperat, Eva $u Department of Pathology, Hôpital Tenon, Sorbonne University, Paris, France
- 700 1_
- $a da Cunha, Isabela Werneck $u Pathology Department, Rede D'OR-Sao Luiz, Sao Paulo, SP, Brazil $1 https://orcid.org/0000000220295139
- 700 1_
- $a Gordetsky, Jennifer B $u Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA $1 https://orcid.org/0000000207452160
- 700 1_
- $a Gupta, Sounak $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a He, Huiying $u Department of Pathology, Health Science Center, Peking University, Beijing, China
- 700 1_
- $a Hirsch, Michelle S $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000287678564
- 700 1_
- $a Humphrey, Peter A $u Department of Pathology, Yale School of Medicine, New Haven, CT, USA
- 700 1_
- $a Kapur, Payal $u Departments of Pathology, Urology, Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a Kojima, Fumiyoshi $u Department of Human Pathology, Wakayama Medical University, Wakayama, Japan
- 700 1_
- $a Lopez, Jose I $u Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, Bizkaia, Spain $1 https://orcid.org/0000000308425348
- 700 1_
- $a Maclean, Fiona $u Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia $u Anatomical Pathology, Douglass Hanly Moir Pathology, Sydney, NSW, Australia
- 700 1_
- $a Magi-Galluzzi, Cristina $u Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA
- 700 1_
- $a McKenney, Jesse K $u Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
- 700 1_
- $a Mehra, Rohit $u Department of Pathology and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA $1 https://orcid.org/0000000269558884
- 700 1_
- $a Menon, Santosh $u Department of Surgical Pathology, Tata Memorial Hospital, Parel, and Homi Bhabha National Institute, Mumbai, India
- 700 1_
- $a Netto, George J $u Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA $1 https://orcid.org/0000000339159134
- 700 1_
- $a Przybycin, Christopher G $u Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
- 700 1_
- $a Rao, Priya $u Department of Pathology MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Rao, Qiu $u Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China $1 https://orcid.org/0000000226741937
- 700 1_
- $a Reuter, Victor E $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Saleeb, Rola M $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Shah, Rajal B $u Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a Smith, Steven C $u Departments of Pathology and Urology, VCU School of Medicine, Richmond, VA, USA $1 https://orcid.org/0000000309824607
- 700 1_
- $a Tickoo, Satish $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Tretiakova, Maria S $u Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA $1 https://orcid.org/0000000208199638
- 700 1_
- $a True, Lawrence $u Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA
- 700 1_
- $a Verkarre, Virginie $u Department of Pathology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France
- 700 1_
- $a Wobker, Sara E $u Departments of Pathology and Laboratory Medicine and Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 700 1_
- $a Zhou, Ming $u Department of Pathology, Tufts Medical Center, Boston, MA, USA
- 700 1_
- $a Gill, Anthony J $u Sydney Medical School, University of Sydney, Sydney, NSW, Australia $u Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Sydney, NSW, Australia $u NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia
- 773 0_
- $w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 34, č. 7 (2021), s. 1392-1424
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33664427 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130105 $b ABA008
- 999 __
- $a ok $b bmc $g 1789808 $s 1163574
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 34 $c 7 $d 1392-1424 $e 20210304 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
- LZP __
- $a Pubmed-20220425
